How to evaluate emerging technologies in cervical cancer screening?

Marc Arbyn, Guglielmo Ronco, Jack Cuzick, Nicolas Wentzensen, Philip E. Castle

Research output: Contribution to journalShort survey

83 Citations (Scopus)

Abstract

Excellent recommendations exist for studying therapeutic and diagnostic questions. We observe that good guidelines on assessment of evidence for screening questions are currently lacking. Guidelines for diagnostic research (STARD), involving systematic application of the reference test (gold standard) to all subjects of large study populations, are not pertinent in situations of screening for disease that is currently not yet present. A five-step framework is proposed for assessing the potential use of a biomarker as a screening tool for cervical cancer: i) correlation studies establishing a trend between the rate of biomarker expression and severity of neoplasia; ii) diagnostic studies in a clinical setting where all women are submitted to verification by the reference standard; iii) biobank-based studies with assessment in archived cytology samples of the biomarker in cervical cancer cases and controls; iv) prospective cohort studies with baseline assessment of the biomarker and monitoring of disease; v) randomised intervention trials aiming to observe reduced incidence of cancer (or its surrogate, severe dysplasia) in the experimental arm at subsequent screening rounds. The 5-phases framework should guide researchers and test developers in planning assessment of new biomarkers and protect clinicians and stakeholders against premature claims for insufficiently evaluated products.

Original languageEnglish (US)
Pages (from-to)2489-2496
Number of pages8
JournalInternational Journal of Cancer
Volume125
Issue number11
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Early Detection of Cancer
Uterine Cervical Neoplasms
Biomarkers
Technology
Guidelines
Cell Biology
Neoplasms
Cohort Studies
Research Personnel
Prospective Studies
Incidence
Research
Population
Therapeutics

Keywords

  • Biomarker
  • Cervical cancer screening
  • Diagnostic test accuracy
  • Guidelines
  • Health technology assessment
  • HPV
  • Human papillomavirus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

How to evaluate emerging technologies in cervical cancer screening? / Arbyn, Marc; Ronco, Guglielmo; Cuzick, Jack; Wentzensen, Nicolas; Castle, Philip E.

In: International Journal of Cancer, Vol. 125, No. 11, 01.12.2009, p. 2489-2496.

Research output: Contribution to journalShort survey

Arbyn, Marc ; Ronco, Guglielmo ; Cuzick, Jack ; Wentzensen, Nicolas ; Castle, Philip E. / How to evaluate emerging technologies in cervical cancer screening?. In: International Journal of Cancer. 2009 ; Vol. 125, No. 11. pp. 2489-2496.
@article{0ea65b2f47b141148480e0de5e6440a2,
title = "How to evaluate emerging technologies in cervical cancer screening?",
abstract = "Excellent recommendations exist for studying therapeutic and diagnostic questions. We observe that good guidelines on assessment of evidence for screening questions are currently lacking. Guidelines for diagnostic research (STARD), involving systematic application of the reference test (gold standard) to all subjects of large study populations, are not pertinent in situations of screening for disease that is currently not yet present. A five-step framework is proposed for assessing the potential use of a biomarker as a screening tool for cervical cancer: i) correlation studies establishing a trend between the rate of biomarker expression and severity of neoplasia; ii) diagnostic studies in a clinical setting where all women are submitted to verification by the reference standard; iii) biobank-based studies with assessment in archived cytology samples of the biomarker in cervical cancer cases and controls; iv) prospective cohort studies with baseline assessment of the biomarker and monitoring of disease; v) randomised intervention trials aiming to observe reduced incidence of cancer (or its surrogate, severe dysplasia) in the experimental arm at subsequent screening rounds. The 5-phases framework should guide researchers and test developers in planning assessment of new biomarkers and protect clinicians and stakeholders against premature claims for insufficiently evaluated products.",
keywords = "Biomarker, Cervical cancer screening, Diagnostic test accuracy, Guidelines, Health technology assessment, HPV, Human papillomavirus",
author = "Marc Arbyn and Guglielmo Ronco and Jack Cuzick and Nicolas Wentzensen and Castle, {Philip E.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1002/ijc.24774",
language = "English (US)",
volume = "125",
pages = "2489--2496",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - How to evaluate emerging technologies in cervical cancer screening?

AU - Arbyn, Marc

AU - Ronco, Guglielmo

AU - Cuzick, Jack

AU - Wentzensen, Nicolas

AU - Castle, Philip E.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Excellent recommendations exist for studying therapeutic and diagnostic questions. We observe that good guidelines on assessment of evidence for screening questions are currently lacking. Guidelines for diagnostic research (STARD), involving systematic application of the reference test (gold standard) to all subjects of large study populations, are not pertinent in situations of screening for disease that is currently not yet present. A five-step framework is proposed for assessing the potential use of a biomarker as a screening tool for cervical cancer: i) correlation studies establishing a trend between the rate of biomarker expression and severity of neoplasia; ii) diagnostic studies in a clinical setting where all women are submitted to verification by the reference standard; iii) biobank-based studies with assessment in archived cytology samples of the biomarker in cervical cancer cases and controls; iv) prospective cohort studies with baseline assessment of the biomarker and monitoring of disease; v) randomised intervention trials aiming to observe reduced incidence of cancer (or its surrogate, severe dysplasia) in the experimental arm at subsequent screening rounds. The 5-phases framework should guide researchers and test developers in planning assessment of new biomarkers and protect clinicians and stakeholders against premature claims for insufficiently evaluated products.

AB - Excellent recommendations exist for studying therapeutic and diagnostic questions. We observe that good guidelines on assessment of evidence for screening questions are currently lacking. Guidelines for diagnostic research (STARD), involving systematic application of the reference test (gold standard) to all subjects of large study populations, are not pertinent in situations of screening for disease that is currently not yet present. A five-step framework is proposed for assessing the potential use of a biomarker as a screening tool for cervical cancer: i) correlation studies establishing a trend between the rate of biomarker expression and severity of neoplasia; ii) diagnostic studies in a clinical setting where all women are submitted to verification by the reference standard; iii) biobank-based studies with assessment in archived cytology samples of the biomarker in cervical cancer cases and controls; iv) prospective cohort studies with baseline assessment of the biomarker and monitoring of disease; v) randomised intervention trials aiming to observe reduced incidence of cancer (or its surrogate, severe dysplasia) in the experimental arm at subsequent screening rounds. The 5-phases framework should guide researchers and test developers in planning assessment of new biomarkers and protect clinicians and stakeholders against premature claims for insufficiently evaluated products.

KW - Biomarker

KW - Cervical cancer screening

KW - Diagnostic test accuracy

KW - Guidelines

KW - Health technology assessment

KW - HPV

KW - Human papillomavirus

UR - http://www.scopus.com/inward/record.url?scp=70350738496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350738496&partnerID=8YFLogxK

U2 - 10.1002/ijc.24774

DO - 10.1002/ijc.24774

M3 - Short survey

C2 - 19626591

AN - SCOPUS:70350738496

VL - 125

SP - 2489

EP - 2496

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -